Edesa Biotech Stock (NASDAQ:EDSA)
Previous Close
$1.73
52W Range
$1.55 - $5.99
50D Avg
$2.66
200D Avg
$4.02
Market Cap
$5.99M
Avg Vol (3M)
$31.18K
Beta
0.84
Div Yield
-
EDSA Company Profile
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
EDSA Performance
Peer Comparison
Ticker | Company |
---|---|
SNTI | Senti Biosciences, Inc. |
KTTA | Pasithea Therapeutics Corp. |
LGVN | Longeveron Inc. |
ADTX | Aditxt, Inc. |
REVB | Revelation Biosciences, Inc. |
CING | Cingulate Inc. |
NTRB | Nutriband Inc. |
SABS | SAB Biotherapeutics, Inc. |
LIXT | Lixte Biotechnology Holdings, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
VRAX | Virax Biolabs Group Limited |
RNXT | RenovoRx, Inc. |
INDP | Indaptus Therapeutics, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
PCSA | Processa Pharmaceuticals, Inc. |
THRD | Third Harmonic Bio, Inc. |
PSTV | Plus Therapeutics, Inc. |
PALI | Palisade Bio, Inc. |